Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Wahl

Showing results (821-830 of 851) with videos related to

Pageof 86
Sort By:
The Journal of Experimental Medicine|December 6, 2003
Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrenceMasaki Terabe, So Matsui, Jong-Myun Park, et al.
Biofouling|February 20, 2010
Relevance of mytilid shell microtopographies for fouling defence--a global comparisonA V Bers, E R Díaz, B A P da Gama, et al.
Peptides|November 1, 2005
Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptidesKrishnakumar Devadas, Robert A Boykins, Neil J Hardegen, et al.
Genome Biology|November 14, 2013
Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterpartsAdam D Pfefferle, Jason I Herschkowitz, Jerry Usary, et al.
Molecular Carcinogenesis|August 28, 2015
The Trp53 delta proline (Trp53ΔP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor developmentCassandra J Adams, Jennifer S Yu, Jian-Hua Mao, et al.
Cell Reports|December 12, 2019
DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS ClustersMargie N Sutton, Zhen Lu, Yao-Cheng Li, et al.
Pharmacotherapy|May 29, 2014
Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort studyJames A Kaye, Jordi Castellsague, Christine L Bui, et al.
Current Drug Safety|October 12, 2013
Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial usersChristine L Bui, James A Kaye, Jordi Castellsague, et al.
Nature|December 8, 2022
Structural variants drive context-dependent oncogene activation in cancerZhichao Xu, Dong-Sung Lee, Sahaana Chandran, et al.
Journal of Medicinal Chemistry|February 29, 2024
Development of Selective Pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one-Based Mammalian STE20-Like (MST3/4) Kinase InhibitorsMarcel Rak, Amelie Menge, Roberta Tesch, et al.
Pageof 86

Showing results (821-830 of 851) with videos related to

Sort By:
Pageof 86
The Journal of Experimental Medicine|December 6, 2003
Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrenceMasaki Terabe, So Matsui, Jong-Myun Park, et al.
Biofouling|February 20, 2010
Relevance of mytilid shell microtopographies for fouling defence--a global comparisonA V Bers, E R Díaz, B A P da Gama, et al.
Peptides|November 1, 2005
Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptidesKrishnakumar Devadas, Robert A Boykins, Neil J Hardegen, et al.
Genome Biology|November 14, 2013
Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterpartsAdam D Pfefferle, Jason I Herschkowitz, Jerry Usary, et al.
Molecular Carcinogenesis|August 28, 2015
The Trp53 delta proline (Trp53ΔP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor developmentCassandra J Adams, Jennifer S Yu, Jian-Hua Mao, et al.
Cell Reports|December 12, 2019
DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS ClustersMargie N Sutton, Zhen Lu, Yao-Cheng Li, et al.
Pharmacotherapy|May 29, 2014
Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort studyJames A Kaye, Jordi Castellsague, Christine L Bui, et al.
Current Drug Safety|October 12, 2013
Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial usersChristine L Bui, James A Kaye, Jordi Castellsague, et al.
Nature|December 8, 2022
Structural variants drive context-dependent oncogene activation in cancerZhichao Xu, Dong-Sung Lee, Sahaana Chandran, et al.
Journal of Medicinal Chemistry|February 29, 2024
Development of Selective Pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one-Based Mammalian STE20-Like (MST3/4) Kinase InhibitorsMarcel Rak, Amelie Menge, Roberta Tesch, et al.
Pageof 86